We provide compounds that may be useful as CPS1 inhibitors. These compounds may be useful, for example, in the treatment of cancer.

Disclosed are compounds of formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII-selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

Disclosed are compounds of formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII-selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

The present disclosure relates to a composition having a structure that includes ##STR00001##
where R.sub.1 includes at least one of hydrogen, carbon, and/or fluorine, and includes a covalent bond. In some embodiments of the present disclosure, R.sub.1 may include at least one of hydrogen, fluorine, a carboxyl group, a hydroxyl group, an alkoxy group, and/or a hydrocarbon chain. In some embodiments of the present disclosure, the composition may be derived from at least one of ##STR00002##
In some embodiments of the present disclosure, at least a portion of the composition may be bioderived.

The present disclosure relates to a composition having a structure that includes ##STR00001##
where R.sub.1 includes at least one of hydrogen, carbon, and/or fluorine, and includes a covalent bond. In some embodiments of the present disclosure, R.sub.1 may include at least one of hydrogen, fluorine, a carboxyl group, a hydroxyl group, an alkoxy group, and/or a hydrocarbon chain. In some embodiments of the present disclosure, the composition may be derived from at least one of ##STR00002##
In some embodiments of the present disclosure, at least a portion of the composition may be bioderived.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

##STR00001##

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

##STR00001##

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Provided herein are pyridine and pyrimidine carboxylates and their derivatives, and compositions and methods of use thereof as herbicides.

Provided herein are pyridine and pyrimidine carboxylates and their derivatives, and compositions and methods of use thereof as herbicides.

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).